ZYZhentao Yu

Zhentao Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhentao Yu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Wang

    Department of Minimally Invasive Surgery, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumour Research Institute, Capital Medical University, Beijing, China

    2 shared publications
  • Jianfei Zhu

    Department of thoracic surgery, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, China

    2 shared publications
  • Kai Ma

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    2 shared publications
  • Ran Yang

    Department of Thoracic Surgery, Anyang Tumour Hospital, The Affiliated Anyang Tumour Hospital of Henan University of Science and Technology, Anyang 455000, China

    2 shared publications
  • Xin Yu

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    2 shared publications
  • Bai-Hua Zhang

    Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    1 shared publication

Latest Publications

  • Open Access

    Impact of time-of-day and timing interval of neoadjuvant immunotherapy and chemotherapy infusions among patients with operable NSCLC using the inverse probability of treatment weighting method: a dual-center, retrospective study

    by Xiang-Yang Yu, Wen-Yu Zhai, Zheng-Zheng Xia, Kai Ma, Bai-Hua Zhang, Xin Yu, Sheng-Cheng Lin, Xiao-Tong Guo, Ze-Rui Zhao, Zhen-Tao Yu

    Background: Although multiple studies have confirmed that adjusting the time-of-day (ToDA) of immunotherapy and timing interval (TI) of chemoimmunotherapy can improve long-term outcomes in patients with advanced non-small cell lung cancer (NSCLC), whether this model similarly improves survival among patients with operable NSCLC has not been reported. Patients and methods: This dual-center, retrospective study included adult patients who received neoadjuvant chemoimmunotherapy (neoCIT) for clinical stage T1-4N0-3M0 NSCLC between January 2019 and December 2024. The impact of the ToDA of neoadjuvant immunotherapy (neoIO) on the efficacy and safety were analyzed. In addition, the inverse probability of treatment weighting (IPTW)-weighted Cox regression model was used to compare disease-free survival (DFS) and overall survival (OS) between patients who received either ≥75% (≥75% group) or P = 0.122). Pathologic complete response occurred in 31.7% of the patients in the ≥75% group and in 20.0% of those in the P = 0.177); major pathologic response occurred in 59.3% and 48.9%, respectively ( P = 0.300). According to the results of the IPTW-weighted univariate Cox analysis, patients in the P = 0.065) and OS (68.3% vs. 89.1%; P = 0.033). These findings remained robust to multivariate Cox regression models (DFS: hazard ratio [HR]ffoo, 2.858; 95% confidence intervals [CIs]: 1.239-6.692; P = 0.014; and OS: HR, 7.625; 95% CIs: 1.112-52.272; P = 0.039). Additionally, a shorter mean TI of patients who received neoCIT infusions (P = 0.035). Conclusions: Although early infusions of most neoIO drugs did not affect safety or efficacy, it showed a potential trend toward improving long-term survival. The corresponding immune microenvironment and molecular mechanisms need further exploration to guide the design of future prospective clinical studies.

  • Open Access

    Treatment patterns and clinical outcomes of neoadjuvant chemoimmunotherapy for patients with resected oesophageal squamous cell carcinoma: a Chinese multicentre retrospective study

    by Xiangyang Yu, Jianfei Zhu, Feng Wang, Kai Ma, Xiaotong Guo, Baihua Zhang, Lixu Wang, Xin Yu, Shengcheng Lin, Calvin S. H. Ng, et al.

    Background: Several clinical trials of neoadjuvant chemoimmunotherapy (neoCIT) for patients with locally advanced oesophageal carcinoma have been reported recently, with promising anti-tumour efficacy. However, systematic evaluation of the treatment patterns and clinical outcomes in a real-world cohort is lacking. Objectives: This study aimed to describe the real-world treatment patterns and short- and long-term outcomes of neoCIT in patients with resected oesophageal squamous cell carcinoma (ESCC). Design: A multicentre retrospective cohort study. Methods: Data from patients with resected ESCC who received neoCIT in routine clinical practice between January 2020 and December 2022 were retrospectively collected from three tertiary centres in China. Results: A total of 324 consecutive patients were enrolled, and the majority (82.4%) received two cycles of neoCIT. In total, 225 patients achieved a radiographic partial response (PR), resulting in an objective response rate of 69.4%. The rates of minimally invasive oesophagectomy and radical resection were 71.9% and 98.5%, respectively. Fifty-nine patients (18.2%) experienced postoperative complications, and the most common complication was anastomotic leakage (10.2%). The pathological complete response and major pathological response rates were 27.2% and 37.0%, respectively. As of August 31, 2024, the median follow-up was 24.8 months. The estimated 3-year rates of disease-free survival and overall survival were 62.3% and 71.5%, respectively. Multivariate analyses revealed that tumour grade ( p = 0.047), number of neoadjuvant therapy cycles ( p = 0.042), resection status ( p = 0.043), pathological N stage ( p < 0.001) and adjuvant treatment ( p < 0.001) were independent prognostic factors for disease-free survival. However, advanced pathological N stage was identified as the sole independent factor that correlated with worse overall survival ( p < 0.001). Conclusion: This real-world study validates the clinical efficacy and safety of neoCIT for resected oesophageal squamous cell carcinoma while demonstrating encouraging survival outcomes.

  • Open Access

    Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture

    by Jiaxin Wang, Zhilin Sui, Wei Huang, Zhentao Yu, Ling Guo

    Patient-derived tumor organoids (PDTOs) shows great potential as a preclinical model. However, the current methods for establishing PDTOs primarily focus on modulating local properties, such as sub-micrometer topographies. Nevertheless, they neglect to capture the global millimeter or intermediate mesoscale architecture that have been demonstrated to influence tumor response to therapeutic treatment and tumor progression. In this study, we present a rapid technique for generating collagen bundles with an average length of 90 ± 27 μm and a mean diameter of 5 ± 1.5 μm from tumor tissue debris that underwent mechanical agitation following enzymatic digestion. The collagen bundles were subsequently utilized for the fabrication of biomimetic hydrogels, incorporating microbial transglutaminase (mTG) crosslinked gelatin. These biomimetic hydrogels, referred to as MC-gel, were specifically designed for patient-derived tumor organoids. The lung cancer organoids cultured in MC-gel exhibited larger diameters and higher cell viability compared to those cultured in gels lacking the mesoscale collagen bundle; moreover, their irregular morphology more closely resembled that observed in vivo. The MC-gel-based lung cancer organoids effectively replicated the histology and mutational landscapes observed in the original donor patient’s tumor tissue. Additionally, these lung cancer organoids showed a remarkable similarity in their gene expression and drug response across different matrices. This recently developed model holds great potential for investigating the occurrence, progression, metastasis, and management of tumors, thereby offering opportunities for personalized medicine and customized treatment options.